de Oliveira André Luiz Malavasi Longo, Paschôa Adilson Ferraz, Marques Marcos Arêas
Centro de Referência da Saúde da Mulher do Estado de São Paulo, Obstetrícia e Ginecologia, São Paulo, SP, Brasil.
Hospital da Beneficência Portuguesa de São Paulo, Cirurgia Vascular, São Paulo, SP, Brasil.
J Vasc Bras. 2020 Jul 6;19:e20190148. doi: 10.1590/1677-5449.190148.
In countries that have controlled classic causes of maternal death, such as eclampsia and hemorrhage, venous thromboembolism (VTE) has become the major concern. Prevention of VTE during pregnancy and postpartum by applying guidelines and implementing pharmacoprophylaxis is still the best strategy to reduce occurrence of this complication. Hormonal contraceptives and hormone replacement therapy also increase the risk of VTE, but women cannot be deprived of their benefits, which increase their freedom at childbearing age and reduce their symptoms at menopause. Both indiscriminate use and unmotivated prohibition are inappropriate. Contraceptive and hormone replacement methods should be chosen with care, evaluating the patients' contraindications, eligibility criteria, and autonomy. This article presents a nonsystematic review of recent literature with the aim of evaluating and summarizing the associations between VTE and clinical situations peculiar to women.
在已经控制了子痫和出血等孕产妇死亡经典病因的国家，静脉血栓栓塞（VTE）已成为主要关注点。通过应用指南和实施药物预防来预防孕期和产后的VTE仍然是降低这种并发症发生率的最佳策略。激素避孕药和激素替代疗法也会增加VTE风险，但不能剥夺女性使用这些药物所带来的益处，这些益处能增加她们育龄期的自由度并减轻绝经后的症状。不加区分地使用和毫无理由地禁止都是不合适的。应谨慎选择避孕和激素替代方法，评估患者的禁忌证、适用标准和自主性。本文对近期文献进行了非系统性综述，目的是评估和总结VTE与女性特有临床情况之间的关联。
